Advertisement

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Arghya Ray, Sandra W. Cowan-Jacob, Paul W. Manley, Jürgen Mestan and James D. Griffin

Article Information

Citation 
vol. 109 no. 11 5011-5015
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted January 12, 2006
  • Accepted December 13, 2006
  • Published online May 23, 2007.

Article Versions


Contributors 
  • Arghya Ray, 1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;
  • Sandra W. Cowan-Jacob, 2Novartis Institutes for BioMedical Research, Basel, Switzerland
  • Paul W. Manley, 2Novartis Institutes for BioMedical Research, Basel, Switzerland
  • Jürgen Mestan, 2Novartis Institutes for BioMedical Research, Basel, Switzerland
  • James D. Griffin, 1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output